Physician

Michael Robertson, MD

According to 2025 Medicare claims, Michael Robertson, MD (NPI: 1093717027) practices nephrology in the Rockford, IL market, with the plurality of this provider's patient population coming from Winnebago, IL. This provider's primary affiliated billing organization is RNA OF ROCKFORD, PLLC (NPI: 1336326388; TIN: 26-1497110) and primary practice location at 61107-5089. Robertson is affiliated with the IRCCO (ACO ID: A2619) and OSF Healthcare System (ACO ID: A3289), participating under the MSSP model.

Robertson's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,018 traditional Medicare patients, billed 5,911 HCPCS/CPT codes, and received $349,157 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,492 prescription claims across 523 beneficiaries totaling $527,959 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 36 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $281,954 and ending at $349,157. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $172,797 and ending at $527,959. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,034	11,338	$281,954
2016	1,124	7,799	$426,306
2017	1,187	9,668	$342,205
2018	1,024	5,065	$334,293
2019	1,001	4,853	$280,342
2020	1,175	4,756	$342,040
2021	1,082	4,376	$306,091
2022	1,024	4,015	$280,396
2023	938	3,215	$212,655
2024	1,018	5,911	$349,157

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	276	1,965	$172,797
2016	341	1,935	$272,933
2017	359	2,094	$423,295
2018	346	1,942	$290,085
2019	333	1,575	$167,187
2020	339	1,482	$121,659
2021	383	1,661	$135,153
2022	382	1,763	$155,135
2023	454	1,960	$203,993
2024	523	2,492	$527,959

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	62	$6,517
2018	N/R	73	$6,211
2019	N/R	95	$8,444
2020	N/R	110	$6,496
2021	N/R	72	$4,726
2022	N/R	52	$3,555
2023	N/R	42	$2,892
2024	N/R	36	$2,142

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	589	856	$91
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	196	507	$61
99490	Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month	168	981	$50
99439	Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month	164	545	$38
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	637	997	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	273	16,479	$307,821
Jardiance	Empagliflozin	85	5,778	$108,430
Cinacalcet Hcl	Cinacalcet Hcl	65	3,950	$38,385
Lokelma	Sodium Zirconium Cyclosilicate	29	1,520	$30,256
Sevelamer Carbonate	Sevelamer Carbonate	22	1,814	$2,970

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7515	Cyclosporine, oral, 25 mg	N	N/R	12	$1,321
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	11	$670
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$150

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Michael Robertson, MD?

Tedicare shows public-source Medicare data for Michael Robertson, MD (NPI 1093717027), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Robertson, MD have ACO affiliation data?

Michael Robertson, MD is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619) and OSF Healthcare System (MSSP, ACO ID A3289).

What billing organization is linked to Michael Robertson, MD?

Michael Robertson, MD is linked to RNA OF ROCKFORD, PLLC (billing NPI 1336326388) in the available physician profile data.

Does Michael Robertson, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.